Ieq Capital LLC Raises Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Ieq Capital LLC lifted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 24.5% in the fourth quarter, Holdings Channel reports. The firm owned 67,715 shares of the company’s stock after purchasing an additional 13,322 shares during the period. Ieq Capital LLC’s holdings in Xeris Biopharma were worth $230,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. increased its position in shares of Xeris Biopharma by 10.5% in the fourth quarter. Principal Financial Group Inc. now owns 113,217 shares of the company’s stock worth $384,000 after acquiring an additional 10,748 shares in the last quarter. Rhumbline Advisers increased its position in shares of Xeris Biopharma by 4.3% in the fourth quarter. Rhumbline Advisers now owns 180,964 shares of the company’s stock worth $613,000 after acquiring an additional 7,408 shares in the last quarter. Legato Capital Management LLC acquired a new stake in shares of Xeris Biopharma in the fourth quarter worth $482,000. GPS Wealth Strategies Group LLC increased its holdings in Xeris Biopharma by 6.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company’s stock valued at $227,000 after purchasing an additional 3,900 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its holdings in Xeris Biopharma by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company’s stock valued at $107,000 after purchasing an additional 2,954 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $3.83 on Friday. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.69 and a 1-year high of $4.10. The business has a 50-day moving average of $3.52 and a 200-day moving average of $3.21. The company has a market capitalization of $570.98 million, a PE ratio of -8.51 and a beta of 2.61.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the company. Piper Sandler lowered Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 target price for the company. in a research note on Monday, November 11th. HC Wainwright increased their price objective on shares of Xeris Biopharma from $6.00 to $6.60 and gave the company a “buy” rating in a research report on Monday, November 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $6.00 price objective (up previously from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.